Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Roivant Sciences Ltd shares valued at $1,095,000 were sold by Venker Eric on May 20 ’25. At $10.95 per share, Venker Eric sold 100,000 shares. The insider’s holdings dropped to 1,077,197 shares worth approximately $12.17 million following the completion of this transaction.
Also, Venker Eric purchased 100,000 shares, netting a total of over 1,094,986 in proceeds.
Before that, Ramaswamy Vivek had sold 625,000 shares from its account. In a trade valued at $6,987,500, the 10% Owner traded Roivant Sciences Ltd shares for $11.18 each. Upon closing the transaction, the insider’s holdings decreased to 625,000 shares, worth approximately $442.67 million.
As published in their initiating research note from Wolfe Research on February 15, 2024, Roivant Sciences Ltd [ROIV] has been an Outperform and the price target has been revised to $17. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in early January. As of December 12, 2023, Deutsche Bank has initiated its “Buy” rating for ROIV. Earlier on October 17, 2023, Guggenheim initiated its rating. Their recommendation was “a Buy” for ROIV stock.
Analyzing ROIV Stock Performance
During the last five days, there has been a surge of approximately 3.57%. Over the course of the year, Roivant Sciences Ltd shares have dropped approximately -4.48%. Shares of the company reached a 52-week high of $12.20 on 01/02/25 and a 52-week low of $8.73 on 04/07/25.
Support And Resistance Levels for Roivant Sciences Ltd (ROIV)
According to the 24-hour chart, there is a support level at 10.81, which, if violated, would cause prices to drop to 10.31. In the upper region, resistance lies at 11.58. The next price resistance is at 11.85. RSI (Relative Strength Index) is 59.10 on the 14-day chart, showing neutral technical sentiment.
